Surgery Godfather Chapter 1174 - 1174 925 Brainwashing

Chapter 1174: Chapter 925 Brainwashing Chapter 1174: Chapter 925 Brainwashing New drugs, especially those that are particularly effective in treating tumors, tend to be extrely expensive, and there’s no way around it because the research and developnt costs for new drugs are exceedingly high. Pharmaceutical companies invest vast sums in the R&D of new drugs, and the risks are also extrely high.

In the pharmaceutical industry, there’s a “rule of thirty” regarding the R&D of new drugs: on average, it takes 10 years, costs 1 billion US dollars, and the success rate is less than 10%.

Take, for instance, the investnts in the developnt of the latest cancer and immune drugs. Soone has calculated that, among 20 new drug samples, the average investnt amounts to a staggering 4.46 billion US dollars.

Given such large investnts, such high risks, and such long developnt cycles, no one would be willing to take on such a task without sufficient profit incentives. Once a new drug hits the market, its price is inevitably extrely high, as pharmaceutical companies need to recoup their costs as quickly as possible, rather than earning money slowly over ti.

For example, when new cancer drugs hit the market, pharmaceutical companies never initially considered the poor as their custors. They only wanted to recoup and earn money quickly from the rich.

Despite being vilified by the entire world, it’s undeniable that without these Western pharmaceutical giants leading the way, other companies would not even have a product to copy. Without the original research drugs, there wouldn’t be any cheap generics.

The current market competition chanism for new drugs and dical devices, despite its many flaws, is also relatively reasonable. Currently, there is no alternative chanism in place.

At 1.2 million yuan per injection, Axicabtagene Ciloleucel Injection belongs to CAR-T cell therapy. It is a cell therapy product that Fosun Kite Company has brought into China by introducing Arican technology, and thus it is relatively cheap. It is also the first cell therapy product in China.

Currently, there are 5 CAR-T cell therapy products on the market worldwide, naly Kymriah, Yescarta, Tecartus, Breyanzi, and Abecma. Among these drugs, Kymriah is the most expensive, priced at 4.75 million US dollars in the United States and 31.3 million yen in Japan.

CAR-T is not produced in a standardized assembly line but is a personalized cell therapy thod that requires the production of CAR-T cells for each individual patient.

The preparation process is demanding, with strict quality control and testing required throughout. The entire preparation process takes about one month.

Ordinary immune T cells are extracted from the patient’s body and shipped to the Laboratory using a cold chain transport system. In the Laboratory, the patient’s T cells are modified using genetic engineering technology to form CAR-T cells. These CAR-T cells are then massively expanded, and after strict quality control and testing, they are returned to the hospital via cold chain and injected into the patient.

Once inside the patient’s body, when CAR-T cells encounter tumor cells expressing the corresponding antigen, the CAR-T cells get activated and expanded, exerting their powerful specific killing power to eliminate the tumor cells.

The training cost of the workers who manufacture CAR-T cells is also expensive, averaging 300,000 yuan per worker, which highlights the high cost.

Yang Ping has his own ideas. His personal research and developnt capabilities are strong, and he can, on his own strength, push the entire dical industry forward. However, he absolutely cannot destroy the industry’s healthy competitive chanism. Once this chanism is ruined, by the ti he is old, the entire pharmaceutical market will be chaotic and dysfunctional. Rebuilding such a dynamic chanism would take a long ti.

—

In the System Space Laboratory, Yang Ping had three experints running simultaneously, thanks to the rewards of 13 CNS papers and the establishnt of the Journal “dical” system, where the massive points allowed Yang Ping to conduct three surgeries at the sa ti.

In the large Laboratory space, Yang Ping divided it into three sections. The research on the K factor in the Tumor Laboratory was going smoothly. According to Yang Ping’s experintal steps: find the K factor—analyze the K factor—synthesize the K factor—use the K factor. Now that the third step has been completed, entering the fourth step, the K factor can be synthesized artificially. The experint had reached the final and most difficult step, and only by completing this step, there was a possibility for the K factor to enter clinical trials.

Yang Ping nad this thod of killing tumors K Therapy, also known as Cell Apoptosis Therapy.

CAR-T Therapy is a cellular therapy that uses the principles of immunity, modifying the body’s own T cells.

Yang Ping’s K Therapy, however, uses the cell’s own apoptosis chanism. By controlling the apoptosis chanism in tumor cells, it initiates the apoptosis program in tumor cells, thereby killing them.

If previous tumor-targeted therapies began externally, precisely identifying tumor cells and then employing various thods to kill them,

Yang Ping’s K Therapy starts from inside the tumor cells. It makes tumor cells realize on their own to initiate the self-destruct program and collectively commit suicide, a natural way for the body to eliminate “rebellious” cells.

Yang Ping modified the K factor in various ways, allowing it to safely navigate the blood circulation and eventually combine with the tumor cells, triggering the apoptosis program in the tumor cells.

The cost of trial and error is colossal. Yang Ping made a modification and then ran a test. Repeating this process over and over, no matter how much ti was consud in System Space, the ti converted to reality was negligible.

If this trial and error process were to occur in a real Laboratory, it would be incredibly ti and labor-consuming. For instance, the initial discovery of monoclonal antibody drugs required searching for one antibody out of a library of 10 billion, or even 100 billion antibodies, through a process of sequential screening, and eventually producing a monoclonal antibody. This process involves at least 1000 steps, and not a single step can afford to go wrong.